HIGHLIGHTS
- who: Lina Tang from the Research Institute (IRCCS), Italy of Texas MD Anderson have published the article: Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial, in the Journal: (JOURNAL) of April/30,/2019
- what: This study demonstrated encouraging antitumor activities of anlotinib as second or later line of therapy for recurrent or metastatic primary malignant bone tumors. All patients in this study received adjuvant chemotherapy after surgery compared to 50% in the phase II trial on regorafenib. In the current study, 2 out of the 3 patients with Ewing . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.